Randomized Phase II Trial Evaluation the Addition of the IGF-1R Monoclonal Antibody Receptor Ganitumab to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma

Brief Summary

Type:
Multiple Sites (Solid Tumors)

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT02306161

Study #:
CMH - AEWS1221

Start Date:
Jan 01, 0001

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT02306161

View Complete Trial Details & Eligibility at ClinicalTrials.gov